Saba Yussouf, INVISI CEO reports successful testing against the Monkeypox Genus.


London, United Kingdom Jun 12, 2022 ( – With over 1000 confirmed cases of Monkeypox, demand is surging for a long-lasting protection to slow down this outbreak. Two other biotechnology companies have announced plans to roll out monkeypox PCR tests, signalling urgency to find a protective solution.

INVISI has successfully tested their solution against the vaccinia virus, found in the orthopoxvirus family containing Monkeypox.

Rapid transmission of monkeypox has occurred due to the recent lifting of pandemic restrictions and international travel. The INVISI long lasting spray destroys 99.999% of the related virus with long lasting 24 hour effect on any surface.

The technology is supported with robust research by prestigious foundations and institutions (The Wellcome Trust, University of Cambridge – Cambridge Institute of Therapeutic Immunology & Infectious Disease, King’s College London – The Randall Centre for Cell and Molecular Biophysics, University of Manchester – Manchester Institute of Biotechnology).

Unlike other disinfectants, INVISI is composed of earth’s minerals, completely non-toxic, kind to the environment and all ingredients are sustainably sourced. The Invisi Smart Shield lowers the global carbon footprint by reducing the requirement for toxic cleaning products.

“All modes of transmission of monkeypox has yet to be confirmed, however it is early days. Therefore, it is important that we take all measures we can to ensure we do not have another global pandemic. Applying Invisi smart we would say is a safe precaution and we know preventative measures is the way we can all future proof our lives”- Timi Hesselhoj, CSO, INVISI.

“As social restrictions have been lifted in much of the world, other viruses have rapidly spiked within a society with lower immunity. Our priority is tow combat new outbreaks by using long-lasting antimicrobial coatings to protect our families and businesses.” – Saba Yussouf, CEO, INVSI.

Press enquiries: [email protected]





Leave a Reply

Your email address will not be published. Required fields are marked *